| 1 |
32859280 | Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. | 2021 Sep 7 |
3 |
| 2 |
28794362 | Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. | 2017 Sep 1 |
3 |
| 3 |
25573239 | Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies. | 2015 Mar |
2 |
| 4 |
26475168 | Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. | 2015 Oct 16 |
9 |
| 5 |
23741067 | Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. | 2013 Aug 1 |
1 |
| 6 |
23816762 | Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. | 2013 Dec |
1 |
| 7 |
22949147 | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. | 2012 Oct 1 |
1 |
| 8 |
20180626 | Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? | 2010 Apr |
1 |
| 9 |
20435574 | Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines. | 2010 Apr |
1 |
| 10 |
19529774 | Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. | 2009 Jun 16 |
1 |
| 11 |
18253119 | A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). | 2008 Feb 26 |
2 |
| 12 |
19047118 | Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. | 2008 Dec 1 |
1 |